US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

FUNDX FUTURE FUND OPPORTUNITIES ETF

29.17

+0.04310.15%

Post-market: 29.170.00000.00%16:10 EDT

Volume:12.05K

Turnover:350.71K

Market Cap:233.80M

PE:- -

High:29.17

Open:29.04

Low:29.04

Close:29.13

52wk High:31.30

52wk Low:25.44

Shares:8.02M

Float Shares:8.02M

Volume Ratio:0.48

T/O Rate:0.15%

Dividend:0.49

Dividend Rate:1.70%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Is GH Research’s Rising Loss Per Share Reframing the GHRS Cash Burn Narrative?

Simply Wall St.

RBC Capital Remains a Buy on GH Research (GHRS)

Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), GH Research (GHRS) and Scholar Rock Holding (SRRK)

Halozyme price target raised to $105 from $93 at Morgan Stanley

Halozyme Therapeutics, Inc. : Leerink Partners Raises to Outperform from Market Perform; Raises Target Price to $110 from $83

THOMSON REUTERS

Halozyme Therapeutics, Inc. : Wells Fargo Raises Target Price to $95 from $75

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (CMPX) and Halozyme (HALO)

Halozyme Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook

Halozyme Q2 FY26 GAAP Net Income Rises 39% to USD 229.9 Million; Revenue Increases 48% to USD 481 Million

Halozyme Therapeutics Q2 Adjusted EPS USD 2.28 Vs. IBES Estimate USD 1.84

Halozyme Therapeutics Outlook FY Adjusted EPS USD 8.65-9

THOMSON REUTERS

Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million

Philadelphia Fed President Open to All Rate Path Options, Doesn't Rule Out Policy Tightening

Fed's Paulson Maintains Flexible Stance on Rates, Focusing on Underlying Inflation Trends

Guardant Health is Maintained at Overweight by Morgan Stanley

Guardant Health (GH) Filed A Shelf Registration To Keep Future Funding Options Open

Simply Wall St.

Analysts Conflicted on These Healthcare Names: Guardant Health (GH) and Cardinal Health (CAH)

Guardant Health Shares Climb Following Outlook Raise

RBC Raises Price Target on Guardant Health to $200 From $185, Keeps Outperform Rating

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/FFOX/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FFOX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FFOX\",,,,,undefined,":{"symbol":"FFOX","market":"US","secType":"STK","nameCN":"FUNDX FUTURE FUND OPPORTUNITIES ETF","latestPrice":29.17,"timestamp":1788552000000,"preClose":29.1269,"halted":0,"volume":12050,"hourTrading":{"tag":"盘后","latestPrice":29.17,"preClose":29.17,"latestTime":"16:10 EDT","volume":6,"amount":175.02,"timestamp":1788552604109,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0014797317943208025,"floatShares":8015000,"shares":8015000,"eps":0,"marketStatus":"Market Closed","change":0.0431,"latestTime":"09-04 16:00:00 EDT","open":29.04,"high":29.17,"low":29.04,"amount":350709,"amplitude":0.004463,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788854400000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":29.1269,"sharesOutstanding":7155000,"nav":29.12,"aum":234270400,"dividendRate":0.016963,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":29.17,"preClose":29.17,"latestTime":"16:10 EDT","volume":6,"amount":175.02,"timestamp":1788552604109,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.47991524548608305},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FFOX\",,,,,undefined,":{"symbol":"FFOX","floatShares":8015000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.47991524548608305,"shares":8015000,"dividePrice":0.4948,"high":29.17,"amplitude":0.004463,"preClose":29.1269,"low":29.04,"week52Low":25.44,"pbRate":"--","week52High":31.295,"institutionHeld":0,"latestPrice":29.17,"eps":0,"divideRate":0.016963,"volume":12050,"delay":0,"ttmEps":0,"open":29.04,"prevYearClose":27.27,"prevWeekClose":29.4519,"prevMonthClose":29.2799,"prevQuarterClose":30.29,"fiveDayClose":29.4519,"twentyDayClose":30.7533,"sixtyDayClose":28.13},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FFOX\",params:#limit:5,,,undefined,":[{"date":"2025-12-31","symbol":"FFOX","amount":0.49447507,"announcedDate":"2025-12-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-31","defaultRemindTime":1767191400000,"name":"FUNDX FUTURE FUND OPPORTUNITIES ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-02","payableDate":"2025-12-31","currency":"USD","dateTimestamp":1767157200000,"payDate":"2026-01-02"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FFOX\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-31","recordDate":"2025-12-31","paymentDate":"2026-01-02","value":0.49447507,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FFOX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FFOX\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658660616","title":"Is GH Research’s Rising Loss Per Share Reframing the GHRS Cash Burn Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2658660616","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658660616?lang=en_us&edition=fundamental","pubTime":"2026-08-10 07:38","pubTimestamp":1786318701,"startTime":"0","endTime":"0","summary":"GH Research PLC recently reported second-quarter 2026 results showing a net loss of US$15.15 million, up from US$9.29 million a year earlier, with basic and diluted loss per share from continuing operations rising to US$0.23 from US$0.15.\nFor the first half of 2026, the company’s net loss expanded to US$34.11 million versus US$20.10 million in the prior-year period, highlighting a meaningful increase in cash burn and pressure on its financial profile.\nWe’ll now examine how this widening net...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/is-gh-researchs-rising-loss-per-share-reframing-the-ghrs-cas","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/is-gh-researchs-rising-loss-per-share-reframing-the-ghrs-cas","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4551","FFOX","BK4535","BK4588","BK4007","BK4196","GHRS","GH","LU0889565916.HKD","EKG","PSIL","HELX","BK4539","PTH","GDOC","GNMX","GNOM","LFSC","LU0320765992.SGD","LU0109394709.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657229326","title":"RBC Capital Remains a Buy on GH Research (GHRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657229326","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657229326?lang=en_us&edition=fundamental","pubTime":"2026-08-08 09:45","pubTimestamp":1786153544,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams maintained a Buy rating on GH Research on August 6 and set a price target of $42.00. The company’s shares closed...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","LU0029864427.USD","BK4007","HELX","GNMX","LFSC","BK4207","FFOX","LU0128525929.USD","GHRS","LU0310800379.SGD","GNOM","PSIL","GSIB","BK4588","BK4196","GDOC","LU0889565916.HKD","GH","EKG","LU0109394709.USD","BK4585","PTH","LU0708994859.HKD","BK4539","LU1267930573.SGD","LU0320765992.SGD","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657260426","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), GH Research (GHRS) and Scholar Rock Holding (SRRK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657260426","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657260426?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:30","pubTimestamp":1786134613,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on InMode (INMD), GH Research (GHRS) and Scholar Rock...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-inmode-inmd-gh-research-ghrs-and-scholar-rock-holding-srrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-inmode-inmd-gh-research-ghrs-and-scholar-rock-holding-srrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","XLV","BK4588","HCSG","BK4137","BK4196","LU0128526141.USD","GHRS","LFSC","BK4139","LABU","BK4007","THNR","BK4585","GNOM","BK4082","GNMX","INMD","LU0889565916.HKD","FFOX","HELX","PSIL","SRRK","PTH","IBRN","BK4535","LU0029874061.USD","LU0320765992.SGD","GDOC","EKG","BK4539","GH","XBI","LU0109394709.USD","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657649006","title":"Halozyme price target raised to $105 from $93 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2657649006","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657649006?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:41","pubTimestamp":1786110082,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Sean Laaman raised the firm’s price target on Halozyme (HALO) to $105 from $93 and keeps an Overweight rating on the shares....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/halozyme-price-target-raised-to-105-from-93-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/halozyme-price-target-raised-to-105-from-93-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FFOX","HALO","LU0053671581.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657610585","title":"Halozyme Therapeutics, Inc. : Leerink Partners Raises to Outperform from Market Perform; Raises Target Price to $110 from $83","url":"https://stock-news.laohu8.com/highlight/detail?id=2657610585","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657610585?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:04","pubTimestamp":1786100654,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nFWN44411S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0053671581.USD","FFOX","BK4139","HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657461763","title":"Halozyme Therapeutics, Inc. : Wells Fargo Raises Target Price to $95 from $75","url":"https://stock-news.laohu8.com/highlight/detail?id=2657461763","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657461763?lang=en_us&edition=fundamental","pubTime":"2026-08-07 18:46","pubTimestamp":1786099568,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nAZN4TCJNE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0053671581.USD","BK4139","FFOX","HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657364660","title":"Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (CMPX) and Halozyme (HALO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657364660","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657364660?lang=en_us&edition=fundamental","pubTime":"2026-08-07 09:40","pubTimestamp":1786066808,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Compass Therapeutics (CMPX) and Halozyme (HALO) with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-compass-therapeutics-cmpx-and-halozyme-halo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-compass-therapeutics-cmpx-and-halozyme-halo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HALO","HCSG","BK4137","CMPX","FFOX","XBI","LU0128526141.USD","BK4139","LABU","LU0029874061.USD","LU0053671581.USD","BK4588","BK4581","BK4585","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657665956","title":"Halozyme Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657665956","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657665956?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:37","pubTimestamp":1786052254,"startTime":"0","endTime":"0","summary":"Halozyme Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings SummaryHalozyme Therapeutics, Inc.HALO.OQreported quarterly adjusted earnings of $2.28 per share for the quarter en","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4433GL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HALO","FFOX","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657085","title":"Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657085","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657085?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:11","pubTimestamp":1786047072,"startTime":"0","endTime":"0","summary":"Halozyme Q2 revenue jumps 48%, raises 2026 outlookOverviewU.S. biopharma firm's Q2 revenue rose 48% yr/yr, beating analyst expectationsAdjusted EPS for Q2 beat analyst expectationsCompany raised 2026 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431CZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","PBE","IE0009354923.USD","HELX","HALO","LU0053671581.USD","IHE","BK4139","LGND","BK4007","RPRX","KYMR","FFOX","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657548","title":"Halozyme Q2 FY26 GAAP Net Income Rises 39% to USD 229.9 Million; Revenue Increases 48% to USD 481 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657548","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657548?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:04","pubTimestamp":1786046699,"startTime":"0","endTime":"0","summary":"Halozyme Q2 FY26 GAAP net income rises 39% to USD 229.9 million; revenue increases 48% to USD 481 millionHalozyme posted Q2 revenue up 48% year-over-year to USD 481 million, driven by royalty revenue ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL38QhQH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FFOX","LU0053671581.USD","HALO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657765652","title":"Halozyme Therapeutics Q2 Adjusted EPS USD 2.28 Vs. IBES Estimate USD 1.84","url":"https://stock-news.laohu8.com/highlight/detail?id=2657765652","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657765652?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:02","pubTimestamp":1786046521,"startTime":"0","endTime":"0","summary":"BRIEF-Halozyme Therapeutics Q2 Adjusted EPS USD 2.28 Vs. IBES Estimate USD 1.84Aug 06 (Reuters) - Halozyme Therapeutics Q2 operating income USD 287.7 million.Q2 net income USD 229.9 millionQ2 EPS USD 1.9","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXSR1CNH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FFOX","LU0053671581.USD","HALO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657652090","title":"Halozyme Therapeutics Outlook FY Adjusted EPS USD 8.65-9","url":"https://stock-news.laohu8.com/highlight/detail?id=2657652090","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657652090?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:01","pubTimestamp":1786046461,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXSR1CNH:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0053671581.USD","FFOX","BK4139","HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657726576","title":"Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657726576","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657726576?lang=en_us&edition=fundamental","pubTime":"2026-08-06 05:11","pubTimestamp":1785964302,"startTime":"0","endTime":"0","summary":"Guardant Health director Ian T. Clark disposes of common shares worth $2.25 millionGuardant Health director Ian T. Clark reported option exercises on Aug. 4, 2026, acquiring 9,088 common shares at USD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL7mNXxZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","EKG","GNOM","GH","HELX","BK4196","BK4551","LFSC","LU0109394709.USD","PTH","BK4585","GDOC","GNMX","FFOX","BK4588","LU0889565916.HKD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129270413","title":"Philadelphia Fed President Open to All Rate Path Options, Doesn't Rule Out Policy Tightening","url":"https://stock-news.laohu8.com/highlight/detail?id=1129270413","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129270413?lang=en_us&edition=fundamental","pubTime":"2026-08-04 23:10","pubTimestamp":1785856224,"startTime":"0","endTime":"0","summary":"The Philadelphia Fed President, Anna Paulson, who will have a vote on the Federal Open Market Committee (FOMC) in 2026, stated on Tuesday that she remains open to the future path of interest rates,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FITZ","FNK","KDRN","NUAG","SECR","TAXX","FNCL","BK4585","GMOC","BKLN","BK4588","DVVY","DFLV","SCYB","CGUI","TXXI","CIK","THRV","FFOX","BCFN","IBHJ","SROI","EVNT","SLWS","VSHY","JFLX","LQID","PFLD","IBCE","BUYO","BUCK","EVG","MFSB","JAAA","QMY","PAYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199799752","title":"Fed's Paulson Maintains Flexible Stance on Rates, Focusing on Underlying Inflation Trends","url":"https://stock-news.laohu8.com/highlight/detail?id=1199799752","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199799752?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:01","pubTimestamp":1785848497,"startTime":"0","endTime":"0","summary":"Federal Reserve officials continue to show diverging views on the outlook for interest rates.Philadelphia Fed President Anna Paulson, a 2026 FOMC voter, stated Tuesday that she will keep an open mind...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPYU","BWX","FNCL","SMAX","EDV","TLTW","BBLB","MMAX","HYG","MINT","TBJL","KBE","JFLX","NUAG","MESmain","UUP","WAMA","BK4559","US3Y.BOND","MYCN","US12M.BOND","US30Y.BOND","TCPB","ZROZ","GOVT","SPYH","KRX","EBUF","SPYM","US7Y.BOND","KDRN","LQID","FITZ","SCYB","XLF","UBmain","TLH","DFLV","SKRE","IAT","SGOV","JPST","GBIL","SROI","BSV","MFSB","TNmain","BIL","SCHO","SPYQ","US5Y.BOND","DBND","BK4588","PFLD","SH","TAXX","EVNT","MUNX","XLRI","KRE",".SPX","BOXX","ZBmain","ISHG","SPY","BK4534","HK0000934320.USD","BKLN","EMPB","BBSB","HMOP","TYO","SDS","SLWS","NELS","TBT","CGUI","SPDN","TLTX","OEF","VGSH","AGG","EVG","BCFN","IVV","VCSH","BOND","SECR","ZTmain","ESmain","GOLY","BK4561","USHY","BOXA","TXXI","SPXU","JHCR","IEI","UPRO","UBT","TFJL","SPUU","CIVG","FFOX","VGLT","SHY","KBWB","LIAJ","BBIB","SPYB","UDN","SPXL","US10Y.BOND","PAYH","TLTI","VSHY","BWZ","TBIL","IEF","SSO","PBDC","IGOV","YSPY","BK4504","SPXS","RIZE","FAZ","LSTB","BK4550","NEMD","FNK","US2Y.BOND","DVVY","SPYI","MUB","XBIL","DPST","TIP","DMAX","IBHJ","VEXC","VGIT","JAAA","SHV","BK4535","TSYW","RAUS","BUCK","HIBL","VOO","LQD","IBCE","VFH","GMOC","OEX","BK4581","FLGV","BK4585","CIK","NGHT","US6M.BOND","QMY","THRV","OOQB","BND","VCIT","CGUS","TMF","ZFmain","JULD","FEM","BUYO","TLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656556059","title":"Guardant Health is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2656556059","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656556059?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:44","pubTimestamp":1785847440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","LU0109394709.USD","BK4535","LU0320765992.SGD","PTH","BK4585","HELX","GH","LFSC","EKG","FFOX","GDOC","GNMX","BK4588","LU0889565916.HKD","GNOM","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656753914","title":"Guardant Health (GH) Filed A Shelf Registration To Keep Future Funding Options Open","url":"https://stock-news.laohu8.com/highlight/detail?id=2656753914","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656753914?lang=en_us&edition=fundamental","pubTime":"2026-08-04 15:22","pubTimestamp":1785828122,"startTime":"0","endTime":"0","summary":"Guardant Health filed a universal shelf registration statement, allowing it to issue various securities in the future.\nThe filing gives the company flexibility to raise capital through debt, equity, or hybrid instruments as needed.\nThis development could be used to support future financing, potential acquisitions, or balance sheet adjustments.\n\nGuardant Health, listed as NasdaqGS:GH, now has formal flexibility to raise funds through a range of securities. The stock last closed at $158.83 and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-filed-a-shelf-registration-to-keep-future","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-filed-a-shelf-registration-to-keep-future","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0109394709.USD","LFSC","BK4588","LU0320765992.SGD","FFOX","EKG","GH","PTH","BK4196","GNMX","GDOC","HELX","GNOM","BK4551","BK4585","BK4535","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656697372","title":"Analysts Conflicted on These Healthcare Names: Guardant Health (GH) and Cardinal Health (CAH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656697372","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656697372?lang=en_us&edition=fundamental","pubTime":"2026-08-03 22:00","pubTimestamp":1785765628,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Guardant Health (GH) and Cardinal Health (CAH). Gu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-guardant-health-gh-and-cardinal-health-cah-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-guardant-health-gh-and-cardinal-health-cah-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","LU0310799852.SGD","LU0072461881.USD","XLV","LU0310800965.SGD","LU1571399168.USD","LU0889565916.HKD","BK4585","FFOX","PTH","LU0162691827.USD","GNMX","BK4196","LU0109394709.USD","LU0128525689.USD","LU1880398554.USD","LU1880398471.USD","LU1267930813.SGD","BK4551","LU0320765992.SGD","LU0154236417.USD","LU1983299246.USD","LU0006061336.USD","LU1267930490.SGD","LU0128526141.USD","LABU","GNOM","LU0211328371.USD","LU0889566641.SGD","LU0792757196.USD","LU0029874061.USD","LU1267930227.SGD","BK4588","GH","LU0211327993.USD","XBI","BK4137","HCSG","EKG","CAH","GDOC","BK4175","BK4581","LU0052756011.USD","HELX","SG9999001440.SGD","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655885398","title":"Guardant Health Shares Climb Following Outlook Raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2655885398","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655885398?lang=en_us&edition=fundamental","pubTime":"2026-07-31 23:54","pubTimestamp":1785513240,"startTime":"0","endTime":"0","summary":"Shares of Guardant Health are trading higher after the company raised its full-year revenue outlook and reported higher-than-expected sales during the second quarter.The stock rose 6.1%, to $161.69, o","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4585","BK4535","LU0320765992.SGD","LFSC","BK4588","GH","PTH","BK4196","BK4551","HELX","FFOX","GDOC","EKG","GNOM","LU0889565916.HKD","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655912361","title":"RBC Raises Price Target on Guardant Health to $200 From $185, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2655912361","media":"MT Newswires Live","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655912361?lang=en_us&edition=fundamental","pubTime":"2026-07-31 21:16","pubTimestamp":1785503760,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) has an average rating of buy and mean price target of $191.09, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4196","BK4588","GH","BK4551","EKG","GNOM","LU0109394709.USD","GDOC","LU0889565916.HKD","LFSC","BK4535","GNMX","HELX","PTH","LU0320765992.SGD","FFOX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":74,"code":"91000000","status":"200"}]}}